This time, Aagami has a new client from South Korea. The recent trips to the country has been fruitful. Apart from this new assignment, more are in discussion. 

The assignment received is for outlicensing client's Anti-Retinal-Disease and Anti-cancer Drugs. 

Client has a novel and leading-edge HTS anti-HIV drug screening technique and Novel CPP technique and molecules. The mandate received is for North America region.